Business Context and Reporting Period
P3 Health Partners Inc. filed this Form 8-K on March 31, 2023, reporting events occurring March 30, 2023. The filing concerns a proposed private placement and related agreements; it does not provide operating results for a reporting period.
Financing and Key Terms
- The company entered into a Securities Purchase Agreement to issue approximately 79.9 million units.
- Institutional investors will pay approximately $1.12 per unit, while employees and consultants will pay approximately $1.19 per unit.
- Each unit consists of one Class A common share and 0.75 of a warrant exercisable at $1.13 per share.
- The transaction includes approximately 69.2 million common shares, warrants to purchase approximately 59.9 million common shares, and pre-funded warrants to purchase approximately 10.8 million common shares.
- Aggregate gross proceeds are expected to be approximately $89.5 million, subject to the transaction closing.
- Chicago Pacific Partners-affiliated entities agreed to purchase approximately 52.8 million common shares, approximately 10.8 million pre-funded warrants, and approximately 47.6 million warrants for approximately $71 million.
- Pre-funded warrants have an exercise price of $0.0001 per share. Their exercise price and the number of shares underlying the warrants are subject to customary adjustments for certain corporate actions.
Material Changes, Governance, and Investor Rights
- The private placement is expected to close on April 6, 2023, subject to customary closing conditions. The filing does not state that the closing had occurred as of the filing date.
- The securities are being sold in an unregistered offering under Section 4(a)(2) of the Securities Act and Regulation D.
- At closing, the company expects to enter into a registration rights agreement requiring it to file a resale registration statement within 30 days and use reasonable best efforts to obtain effectiveness within 120 days after filing.
- For as long as CPF-affiliated parties own at least 40% of the company’s outstanding common stock, they will have the right to designate one additional independent director and receive certain information and protective rights.
- CPF-affiliated parties agreed to a standstill restricting their ownership to 49.99% of the company’s common stock through June 30, 2024. Warrants also include a 49.99% beneficial-ownership limitation on CPF exercise.
Financial Metrics, Liquidity, and Outlook
The filing does not provide revenue, profit, cash flow, margins, debt balances, liquidity balances, operating guidance, or a use-of-proceeds schedule. The approximately $89.5 million of gross proceeds would increase liquidity if the transaction closes, but the filing does not quantify net proceeds or describe their intended use.
Risks and Unusual Items
- The financing remains subject to closing conditions and may not be completed on the expected date or at all.
- Issuance of the shares, pre-funded warrants, and warrants will result in substantial potential dilution to existing stockholders, including additional dilution if warrants are exercised.
- CPF’s investment and related governance, information, and protective rights could give it significant influence over the company.
- The securities are initially unregistered and subject to resale-registration requirements and contractual limitations.
Important Facts to Verify
- Whether the private placement closed on or around April 6, 2023 and the actual securities issued.
- The company’s net cash proceeds after fees and expenses and the planned use of those proceeds.
- The post-closing share count and potential dilution from all warrants and pre-funded warrants.
- The filing and effectiveness status of the resale registration statement.
- CPF’s resulting ownership percentage and exercise of its board designation and other rights.